Loading
Prostate Cancer Treatment and Research / Prostate Cancer Diagnosis and Treatment / Cancer, Lipids, and Metabolism · Journal article
JAMA Oncology · August 13, 2026
Well-designed and adequately powered for the question it asks.
This large retrospective cohort study documents that metabolic syndrome develops in nearly 40% of men during the first year of concurrent ADT and ARPI therapy for prostate cancer, with incidence varying by age and ARPI type. The finding is based on a well-powered national cohort without prior metabolic dysfunction, but lacks a comparator arm and relies on administrative health records, so it establishes the magnitude and timing of metabolic burden rather than causal attribution or relative risk.
Retrospective cohort study. 16,924 adult men with prostate cancer initiating treatment with concurrent ADT and ARPI (abiraterone acetate, enzalutamide, apalutamide, or darolutamide) without prior metabolic syndrome or component diagnoses. Mean age 73.1 years (SD 9.1); 65.5% non-Hispanic White, 21.0% non-Hispanic Black, 5.4% H…. Intervention: Concurrent androgen deprivation therapy and androgen receptor pathway inhibitor therapy (abiraterone acetate, enzalutamide, apalutamide, or darolutamide), with index date defined as first date of therapeutic overlap. n = 16,924. United States (national deidentified health record dataset).
Cumulative incidence of metabolic syndrome reached nearly 40% during first year following ADT-ARPI initiation in 16,924 men Highest incidence of metabolic syndrome among patients aged 70 to 79 years: 51.7 events per 1000 person-months (95% CI, 50.7–53.9) Hypertension was the most frequently documented component outcome of metabolic syndrome
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that metabolic abnormalities, particularly hypertension, develop rapidly and frequently in men on ADT-ARPI and warrant systematic monitoring and multidisciplinary intervention from treatment initiation, especially in men aged 70–79 years. The study supports extending surveillance beyond cancer-specific outcomes to include metabolic parameters and cardiometabolic risk.
Large retrospective cohort study with 16,924 patients showing nearly 40% cumulative incidence of metabolic syndrome within one year of ADT-ARPI initiation; well-characterized population and clear clinical outcome with age-stratified analysis, though observational design and lack of unexposed comparator limit causal inference.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that metabolic abnormalities, particularly hypertension, develop rapidly and frequently in men on ADT-ARPI and warrant systematic monitoring and multidisciplinary intervention from treatment initiation, especially in men aged 70–79 years. The study supports extending surveillance beyond cancer-specific outcomes to include metabolic parameters and cardiometabolic risk.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Importance Metabolic syndrome (MetS) includes obesity, insulin resistance, hypertension, and dyslipidemia. While androgen deprivation therapy (ADT) is associated with an increased risk of dyslipidemia, adiposity, and MetS, evidence is limited on the occurrence and timing of metabolic dysfunction among men receiving concurrent androgen receptor pathway inhibitor (ARPI) therapy and whether patterns vary by age. Objective To characterize the occurrence and rate of MetS during the first year following initiation of ADT-ARPI, examine associations with age and ARPI type, and evaluate component metabolic outcomes (secondary end points). Design, Setting, and Participants This retrospective cohort study of adult patients from January 2014 to September 2025 with up to 12 months of follow-up per person used data from a national, deidentified health record dataset (Epic Cosmos) and included patients with prostate cancer who initiated treatment with ADT-ARPI (abiraterone acetate, enzalutamide, apalutamide, and darolutamide) without evidence of MetS or its components before treatment. Data were analyzed between October 2025 and January 2026 (further analyses were done with revisions through May 2026). Exposure Concurrent ADT and ARPI use, with index date defined as the first date of overlap between therapies. Main Outcomes and Measures New-onset MetS during the 12 months following the index date. Secondary outcomes included individual metabolic abnormalities. Results The cohort included 16 924 men with prostate cancer (mean [SD] age, 73.1 [9.1] y; 509 [3.0%] Asian individuals, 912 [5.4%] Hispanic individuals, 3562 [21.0%] non-Hispanic Black individuals, and 11 083 [65.5%] non-Hispanic White individuals). Medical ADT use predominated, and enzalutamide was the most frequently used ARPI. During the first year following initiation of concurrent ADT and ARPI therapy, the cumulative incidence of metabolic syndrome increased steadily, reaching nearly 40%, and varied by age group. Hypertension was the most frequently documented component outcome. Metabolic associations varied by age, with the highest incidence of metabolic syndrome among patients aged 70 to 79 years (51.7 events per 1000 person-months; 95% CI, 50.7-53.9). Heterogeneity in metabolic outcomes by ARPI type was observed in exploratory analyses. Conclusions and Relevance This study found that while ARPIs are standard of care for advanced prostate cancer, metabolic abnormalities were frequently documented shortly after initiation of concurrent ADT and ARPI therapy. This suggests that monitoring should extend beyond cancer-specific outcomes to include early detection of metabolic dysfunction, ideally through multidisciplinary care. The early burden of metabolic abnormalities highlights the need to evaluate scalable interventions addressing cardiometabolic risk in men with prostate cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.